Nootropic activity of acetaminophen against colchicine induced cognitive impairment in rats

Vigneshwaran Pitchaimani,1 Somasundaram Arumugam,1,2 Rajarajan A. Thandavarayan,2 Manisenthilkumar K. Thiyagarajan,1 Rajasekaran Aiyalu,1 Remya Sreedhar,1 Takashi Nakamura2 and Kenichi Watanabe2,*

1KMCH College of Pharmacy, Kovai Estate, Kalapatti Road, Coimbatore – 641048, Tamilnadu, India
2Dept. of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Niigata 956-8603, Japan
3Nehru College of Pharmacy, Pampady, Near Lakkidi Station, Thrivuvilwamala, Thrissur – 680597, Kerala, India

(Received 24 May, 2011; Accepted 8 August, 2011)

Alzheimer’s disease is a devastating neurodegenerative disorder, the most common among the dementing illnesses. Acetaminophen has gaining importance in neurodegenerative diseases by attenuating the dopaminergic neurodegeneration in Caenorhabditis elegans model, decreasing the chemokines and the cytokines and increasing the anti apoptotic protein such as Bcl-2 in neuronal cell culture. The low concentration acetaminophen improved the facilitation to find the hidden platform in Morris Water Maze Test. Also some data suggest that acetaminophen could contribute in neurodegeneration. The present study was aimed to evaluate the effect of acetaminophen against colchicine induced cognitive impairment and oxidative stress in wistar rats. The cognitive learning and memory behaviour was assessed using step through passive avoidance paradigm and acetylcholine esterase activity. The parameters of oxidative stress were assessed by measuring the malondialdehyde, reduced glutathione and catalase levels in the whole brain homogenates. There was a significant memory improvement in the rats received acetaminophen treatment and it has also decreased the acetylcholine esterase enzyme level, confirming its nootropic activity. Acetaminophen neither increases nor decreases the reduced glutathione and catalase in the whole brain homogenates, showing that acetaminophen is devoid of any adverse effect on brain antioxidant defense system.

Key Words: Alzheimer’s disease, Acetaminophen, Learning and memory, colchicine

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and its pathological hallmarks are senile plagues and neurofibrillary tangles.11 Oxidative stress and free radicals are the central to the pathogenesis of AD by forming the neurofibrillary tangles causing irreversible cellular damage and neuronal dysfunction.12 Impaired cortical cholinergic neurotransmission contributes to the amyloid-β (Aβ) pathology and increases the phosphorylation of tau protein.13 The intracerebroventricular administration of colchicine in rats produces cognitive impairment and oxidative stress by disrupting the microtubule assembly and this method can be effectively used as an animal model for AD.4,4 The most logical route toward therapeutic intervention for neurodegenerative diseases involves the identification of small molecules that have the ability to provide neuroprotection. For example, acetaminophen protects hippocampal neurons and PC12 cultures from Aβ peptide-induced oxidative stress through reduction of lipid peroxidation and by lowering cytoplasmic levels of peroxides.13 Quinolinic acid, a neurotoxic metabolite implicated in the pathogenesis of neurodegenerative disease, is inhibited by administration of acetaminophen.15 Acetaminophen also protects dopaminergic neurons in vitro from oxidative damage evoked by acute exposure to 6-hydroxydopamine or excessive levels of dopamine.9 Acetaminophen has been shown to blunt neuronal apoptosis via reduction of the inflammatory transcription factor NF-κB and reduces the inflammatory protein such as chemokines and cytokines.17 Acetaminophen also protects brain endothelial cells against oxidative stress.10 So our aim is to determine nootropic activity of acetaminophen by measuring the acetyl cholinesterase activity in the rat brain homogenates and in vivo step through passive avoidance paradigm task and also to study its effect on brain antioxidant status in colchicine induced neurotoxicity in rats.

Materials and Methods

Animals. Wistar albino rats obtained from the Animal House of the KMCH College of Pharmacy, Coimbatore, and weighing 180–200 g. Following surgery, the animals were kept under standard conditions of light and dark cycle with food and water ad libitum and cages with soft bedding. All the experiments were carried out between 09:00 and 15:00 h. All procedures described were reviewed and approved by the Institutional Animal Ethical Committee (IAEC).

Drug treatment. The administration of colchicine was considered as day 0. The standard drug, donepezil (2 mg/kg/day, p.o.), acetaminophen (15.1 mg/kg/day, p.o.), ascorbic acid monoglucoside (AsAG) (250 mg/kg/day, p.o.) were administered from day 1, 1 h before the experiments, until the end of the study period.

Colchicine-induced cognitive impairment. Surgery was performed according to a protocol previously described by Kumar and Gupta.19 Colchicine was administered via the intracerebroventricular (i.c.v.) route. Briefly, the right lateral ventricle was cannulated in rats under ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) anaesthesia using stereotaxic coordinates, 0.6 mm posterior to the bregma, 1.8 mm right lateral and 2.7 mm below the cortical surface. Colchicine (15 μg/rat), dissolved in 15 μl of artificial cerebrospinal fluid (aCSF; in nM: NaCl 147, KCl 2.9, MgCl2 1.6, CaCl2 1.7 and dextrose 2.2), were slowly injected into the cannulated right lateral ventricle using a 20 μl Hamilton syringe and the needle was held in place for 2 min for proper dispersal of the drug from the tip. The animals were then divided into four groups of six each for treatment with aCSF, acetaminophen, AsAG and donepezil. Sham control groups were subjected to the same surgical procedure and received aCSF.
Behavioral assessment. Step-through passive avoidance apparatus. The apparatus used for passive avoidance training consisted of two compartment box. An illuminated chamber (30 × 21 × 20 cm³) made of transparent plastic was connected by a guillotine door to the dark compartment (30 × 21 × 20 cm³) with black opaque walls and ceiling. The floor of the two compartments was constructed of stainless steel rods (3 mm in diameter, 10 mm apart) through which foot-shock could be delivered from a constant current source. Training procedure. All the experimental groups were first habituated to the apparatus. We placed a rat in the illuminated compartment and 10 s later the guillotine door was raised. Upon entering the dark compartment the door was closed and the rat was taken from the dark compartment into the home cage. The habituation trial was repeated after 30 min and followed by the same interval by the acquisition trial during which the guillotine door was closed and a 50 Hz, 1 mA constant current shock was applied for 2 s immediately after the animal had entered the dark compartment. In all experiments the rat was retrained in the apparatus and received a foot shock each time it re entered the dark compartment in 120 s and if it happens for three times we excluded it from the experiment. Training was terminated when the rat remained in the light compartment for 120 consecutive seconds. All the groups were trained before day 0 and the transfer latencies were assessed in day 7, 14 and day 21.

Retention trial. Recall of this inhibitory stimulus was evaluated on day 7, 14 and 21 post-training by returning the animals into the light compartment and recording their latency to enter the dark compartment (four paws in). If the animal had not entered to the dark compartment within 300 s, it was returned to its cage and a maximum latency of 300 s was recorded. This latency served as a measure of retention performance of the step-through avoidance response (retention latency).

Biochemical tests. Biochemical tests were carried out 24 h after the last behavioural test on day 21 following colchicine injections i.e. on day 22.

Tissue preparation. Animals were sacrificed by decapitation and brains were removed and rinsed with ice-cold isotonic saline. Brain samples were then homogenized with 10 times (w/v) ice cold 0.1 M phosphate buffer (pH 7.4). The homogenates were centrifuged at 10,000 × g for 15 min and aliquots of supernatant were separated and used for biochemical estimation.

Measurement of catalase. Catalase activity was measured by the method of Aebi. [13] A total of 0.1 ml of supernatant is added to cuvette containing 1.9 ml of 50 mM phosphate buffer (pH 7.0). The reaction started by the addition of 1 ml freshly prepared 30 mM H₂O₂. The rate of decomposition of H₂O₂ was measured spectrophotometrically from the changes in absorbance at 240 nm. The activity of catalase was expressed as U/mg protein.[14]

Estimation of reduced glutathione. Glutathione was measured according to the method of Ellman.[15,16] The equal quantity of homogenate was mixed with 10% trichloroacetic acid and centrifuged to separate the proteins. To 0.1 ml of this supernatant, 2 ml of phosphate buffer (pH 8.4), 0.5 ml of 5,5-dithiobis (2-nitrobenzoic acid) and 0.4 ml of double distilled water were added. The mixture was vortexed and the absorbance was read at 412 nm within 15 min. The concentration of reduced glutathione was expressed as μg/g tissue.

Acetyl cholinesterase activity. Acetyl cholinesterase activity is a marker of extended loss of the cholinergic system in the brain. The quantitative measurement of acetyl cholinesterase levels in brain was performed according to the method of Ellman et al.[13] The assay mixture contained 0.05 ml of supernatant, 3 ml of 0.01 M sodium phosphate buffer (pH 8), 0.1 ml of acetylthiocholine iodide and 0.1 ml of DTNB (Ellman reagent). The change in absorbance was measured immediately at 412 nm using spectrophotometer. Results were calculated using molar extinction coefficient of chromophore (1.36 × 10⁴ M⁻¹ cm⁻¹) and expressed as nmols of acetyl choline hydrolysed/g tissue.

Lipid peroxidation. The quantitative measurement of lipid peroxidation in brain was performed according to the method of Wills.[19] The amount of malondialdehyde, a measure of lipid peroxidation was measured by reaction with thiorbarbituric acid at 532 nm using a Perkin Elmer lambda 20 spectrophotometer. The values were calculated using molar extinction coefficient of chromophore (1.56 × 10⁵ M⁻¹ cm⁻¹) and expressed as nmols/g tissue.

Estimation of total protein. The protein content of the brain homogenate was measured by biuret method using bovine serum albumin as standard.

Statistical analysis. The statistical analysis was performed by oneway ANOVA followed by Tukey’s test. p<0.05 is considered to be significant.

Results

Passive avoidance paradigm. In the step through passive avoidance paradigm task on day 7, 14 and 21, significant decrease in the escape latency were found in the colchicine treated rats when compared with the rats received aCSF, whereas the rats treated with acetaminophen showed significant increase when compared with the colchicine treated rats on all the tested days. Similarly the rats treated with donepezil and AsAG also found to have significantly increased escape latency over colchicine group on day 7, 14 and 21 (Fig. 1A–C).

Estimation of acetylcholine esterase enzyme. Central administration of colchicine did not impart any suppression of brain acetylcholine esterase levels as compared to the aCSF treated group, but the rats received acetaminophen had a significant decrease when compared with the colchicine and aCSF group. However the donepezil treated rats also had a significant decrease in acetylcholine esterase levels as compared to the colchicine treated rats (Fig. 2).

Estimation of reduced glutathione. Central administration of colchicine caused a significant depletion of brain reduced glutathione as compared to the aCSF treated rats. The rats in the acetaminophen treatment group did not produce any significant change in the reduced glutathione as compared to the colchicine treated rats. The group receiving the AsAG showed a significant difference when compared with colchicine treated group (Fig. 3A).

Estimation of catalase. Central administration of colchicine did not cause any depletion of brain catalase as compared to the aCSF treated rats. Similarly the rats treated with acetaminophen also did not produce any significant change in the catalase level as compared to the colchicine treated rats. Whereas the group receiving the AsAG showed a significant difference when compared with colchicine treated group (Fig. 3B).

Estimation of MDA. Treatment with colchicine caused a significant elevation in the brain MDA level as compared to the aCSF treated rats. The acetaminophen received rats showed significant reduction in MDA level as compared to the colchicine treated rats. Similarly the rats received the AsAG also showed a significant difference when compared with colchicine treated group (Fig. 3C).

Discussion

Study of anti-neuoinflammatory effects of drugs has become the major research in the treatment of AD.[15,16] The chronic administration of naproxen (20 and 40 mg/kg, p.o.) and valdecoxib (10 mg/kg, p.o.) significantly restored acetyl cholinesterase activity compared to colchicine-injected group.[17] An interesting clinical study suggests that treatment of pain with acetaminophen in nursing home residents with moderate-to-severe dementia facilitated engagement with the environment.[18] Effective management of pain can play an important part in the treatment of AD.
agitation and could reduce the number of unnecessary prescriptions for psychotropic drugs.\(^{(19)}\) Acetaminophen use reduced pain behaviours associated with musculoskeletal pain in this sample of persons with dementia.\(^{(20)}\) The anti-inflammatory effect of acetaminophen in AD has been reported by Landolfi et al.\(^{(21)}\) All of these reports indicate the effect of acetaminophen against behavioural protection in patients with dementia. Apart from the mechanism of pain reduction, there was an interesting report suggesting that the low concentration of acetaminophen improved the facilitation to find the hidden platform in Morris Water Maze test.\(^{(22)}\) In the present study, intracerebroventricular administration of colchicine impaired the cognition by decreasing the escape latencies in the passive avoidance paradigm task. The chronic administration of acetaminophen (15.1 mg/kg, p.o.) had a significant difference in the escape latencies in the passive avoidance paradigm. Also acetaminophen had decreased the enzyme acetylcholine esterase in the whole brain homogenates showing that acetaminophen having nootropic activity. Thus the present study confirms the role of acetaminophen against the cognitive impairment induced by colchicine.

There are few negative reports regarding the consumption of glutathione for the metabolism of acetaminophen. Glutathione consuming effect of acetaminophen could reduce the plasma glutathione concentration. Subsequently, the plasma-derived

---

**Fig. 1.** A–C, Results of step through passive avoidance test on days 7, 14 and 21 respectively. aCSF, rats treated with artificial cerebrospinal fluid; Col, rats treated with intracerebroventricular colchicine; Col + APAP, Col + AsAG and Col + DPZ, rats treated with intracerebroventricular colchicine followed by acetaminophen, ascorbic acid monoglucoside and donepezil respectively. Results are expressed as mean retention latency with standard error. \(***p<0.001\) vs Col, \(**p<0.01, \***p<0.001\) vs aCSF (One-way ANOVA followed by Tukey’s test).

**Fig. 2.** Determination of acetylcholinesterase activity as mentioned by nmol of acetylcholine hydrolysed per g brain tissue. aCSF, rats treated with artificial cerebrospinal fluid; Col, rats treated with intracerebroventricular colchicine; Col + APAP and Col + DPZ, rats treated with intracerebroventricular colchicine followed by acetaminophen and donepezil respectively. Results are expressed as mean retention latency with standard error. \(p<0.05, \***p<0.001\) vs aCSF (One-way ANOVA followed by Tukey’s test).

---

**Fig. 3.** Study of antioxidant parameters in the colchicine induced cognition impaired rats. A, estimation of reduced glutathione (mg/g tissue); B, estimation of catalase activity (Units/mg protein); C, measurement of MDA levels (nmol/mg brain tissue). aCSF, rats treated with artificial cerebrospinal fluid; Col, rats treated with intracerebroventricular colchicine; Col + APAP and Col + AsAG, rats treated with intracerebroventricular colchicine followed by acetaminophen and ascorbic acid monoglucoside respectively. Results are expressed as mean retention latency with standard error. \(***p<0.001\) vs Col, \(**p<0.01\) vs aCSF (One-way ANOVA followed by Tukey’s test).
glutathione supply to the CNS is reduced and the toxic effect of oxidative stress is amplified. New evidence suggests that glutathione cannot cross blood brain barrier and thus the peripheral effect of acetaminophen on glutathione may not influence its level in the brain. In order to study the effect of acetaminophen on brain glutathione, we have measured its level in the brain homogenates. The decreased GSH concentration in the CNS would result in the declined defence against the oxidative stress and promote the neuron loss. The chronic administration of acetaminophen (15.1 mg/kg, p.o.) did not affect the brain GSH level, which shows that peripheral GSH is not the major source in the CNS and acetaminophen is not contributed in neurodegeneration by having any decreasing effect on GSH in the whole brain homogenates.

In addition we have measured the brain catalase levels to determine the effect of acetaminophen on brain antioxidant system. Catalase has a protective role as a hydrogen peroxide degrading enzyme. Inhibition of catalase activity with amino-triazole enhances the cytotoxicity of Alzheimer’s beta amyloid peptide suggests that catalase is involved in the protection of neuronal and non neuronal cells types. Catalase was slightly inhibited (30%) in liver after acetaminophen administration in mice at a single dose of 375 mg/kg. In the present study, acetaminophen (15.1 mg/kg, p.o.) neither increases nor decreases catalase in the whole brain homogenates, confirms that acetaminophen not contributed in neurodegeneration by having any decreasing effect on the enzyme catalase.

To confirm the effect of acetaminophen treatment on antioxidant defense system, we have also measured the brain MDA levels as a measure of lipid peroxidation. The rats treated with acetaminophen were protected from lipid peroxidation indicated by the low MDA levels which is comparable to the anti-lipid peroxidative effect of AsAG. These results suggest that the treatment with acetaminophen did not affect the brain antioxidant defense system and also protects it by preventing lipid peroxidation.

In summary, the present study confirms the nootropic activity of acetaminophen through increasing the escape latency and decreasing the acetyl cholinesterase activity in colchicine induced cognitive impairment in rats. And also suggesting that acetaminophen is devoid of any adverse effect on brain antioxidant system with a potential to prevent lipid peroxidation.

References

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–356.
2. Perry G, Cash DA, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2002; 2: 120–123.
3. Mohandas E, Rajmohan V, Raghu nath B. Neurobiology of Alzheimer’s disease. Indian J Psychiatry 2009; 51: 55–61.
4. Veerendra Kumar MH, Gupta YK. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav 2002; 73: 565–571.
5. Nakayama T, Sawada T. Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav 2002; 71: 119–138.
6. Nakagawa Y, Nakamura S, KaSe Y, Noguchi T, Ishihara T. Colchicine lesions in the rat hippocampus mimic the alterations of several markers in Alzheimer’s disease. Brain Res 1987; 408: 57–64.
7. Bisaglia M, Venezia V, Piccioli P, et al. Acetaminophen protects hippocampal neurons and PC12 cultures from amyloid beta-peptides induced oxidative stress and reduces NF-kappaB activation. Neurochem Int 2002; 41: 43–54.
8. Maharaj H, Maharaj DS, Dasa Y. Acetylhalic acid and acetaminophen protect against oxidative neurotoxicity. Metab Brain Dis 2006; 21: 189–199.
9. Locke CI, Fox SA, Caldwell GA, Caldwell KA. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson’s disease. Neurosci Lett 2008; 439: 129–133.
10. Tripathy D, Grannam P. Acetaminophen protects brain endothelial cells against oxidative stress. Microvasc Res 2009; 77: 289–296.
11. Aebl H. Catalase. In: BergmeyerHU, ed. Methods of Enzymatic Analysis, Vol. II, Academic Press, New York, 1974; 673–678.
12. Ellman GL. Tissue sulphydryl groups. Arch Biochem Biophys 1959; 82: 70–77.
13. Ellman GL, Courtney KD, Andres V Jr., Feather-stone RM. A new and rapid colorimetric determination of acetylcyanilinesterase activity. Biochem Pharmacol 1961; 7: 88–95.
14. Wills ED. Mechanism of lipid peroxide formation in animal tissues. Biochem J 1996; 99: 667–676.